Literature DB >> 2509055

Flagellar antibody stimulated opsonophagocytosis of Pseudomonas aeruginosa associated with response to either a- or b-type flagellar antigen.

T R Anderson1, T C Montie.   

Abstract

Pseudomonas aeruginosa exhibit one of two flagella types: a homogeneous b type, with molecular weight of 53,000, or a heterogeneous a type (subtypes a0, a1, a2, a3, and a4), with molecular weights ranging from 45,000 to 52,000. Pseudomonas aeruginosa flagellar antiserum was shown to promote uptake of radiolabeled bacteria by mouse polymorphonuclear leukocytes. Bacteria were detected directly associated with washed leukocytes and visualized, by electron microscopy, internalized in polymorphonuclear leukocytes. Phagocytosis was specific for the flagella type (a or b) in that homologous flagella serum enhanced uptake three to four times greater than heterologous serum or normal rabbit serum. An a-type antiserum was shown to enhance phagocytosis of four different a-type strains with varying subantigen types, indicating the presence of a common cross-reactive a0 antigen in this flagella type. Phagocytic killing of internalized bacteria was not seen with the addition of only flagellar antiserum.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2509055     DOI: 10.1139/m89-148

Source DB:  PubMed          Journal:  Can J Microbiol        ISSN: 0008-4166            Impact factor:   2.419


  9 in total

1.  Effect of antiflagellar human monoclonal antibody on gut-derived Pseudomonas aeruginosa sepsis in mice.

Authors:  T Matsumoto; K Tateda; S Miyazaki; N Furuya; A Ohno; Y Ishii; Y Hirakata; K Yamaguchi
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

2.  Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines.

Authors:  Victoria L Campodónico; Nicolás J Llosa; Martha Grout; Gerd Döring; Tomás Maira-Litrán; Gerald B Pier
Journal:  Infect Immun       Date:  2009-12-07       Impact factor: 3.441

3.  Generation and characterization of murine antiflagellum monoclonal antibodies that are protective against lethal challenge with Pseudomonas aeruginosa.

Authors:  M J Rosok; M R Stebbins; K Connelly; M E Lostrom; A W Siadak
Journal:  Infect Immun       Date:  1990-12       Impact factor: 3.441

4.  Therapeutic effects of a human antiflagella monoclonal antibody in a neutropenic murine model of Pseudomonas aeruginosa pneumonia.

Authors:  K Oishi; F Sonoda; A Iwagaki; P Ponglertnapagorn; K Watanabe; T Nagatake; A Siadak; M Pollack; K Matsumoto
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

5.  Inhibitory activity on bacterial motility and in vivo protective activity of human monoclonal antibodies against flagella of Pseudomonas aeruginosa.

Authors:  H Ochi; H Ohtsuka; S Yokota; I Uezumi; M Terashima; K Irie; H Noguchi
Journal:  Infect Immun       Date:  1991-02       Impact factor: 3.441

6.  Serum antibody response to Pseudomonas aeruginosa antigens during corneal infection.

Authors:  M J Preston; J M Berk; L D Hazlett; R S Berk
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

7.  Effects of a human antiflagellar monoclonal antibody in combination with antibiotics on Pseudomonas aeruginosa infection.

Authors:  I Uezumi; M Terashima; T Kohzuki; M Kato; K Irie; H Ochi; H Noguchi
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

8.  Immunotherapy with IgY Antibodies toward Outer Membrane Protein F Protects Burned Mice against Pseudomonas aeruginosa Infection.

Authors:  Fatemeh Norouzi; Bahador Behrouz; Mahya Ranjbar; Seyed Latif Mousavi Gargari
Journal:  J Immunol Res       Date:  2020-05-29       Impact factor: 4.818

9.  Cloning, Expression, and Purification of Pseudomonas aeruginosa Flagellin, and Characterization of the Elicited Anti-Flagellin Antibody.

Authors:  Bahador Behrouz; Nour Amirmozafari; Nima Khoramabadi; Mahboobeh Bahroudi; Parisa Legaee; Mehdi Mahdavi
Journal:  Iran Red Crescent Med J       Date:  2016-06-12       Impact factor: 0.611

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.